"Section 26A (powers of central government to prohibit manufacture, etc., of drug and cosmetic in public interest) appears to be only a regulatory power as per the scheme of the Act. There is no other regulatory power.
"So after you have granted licence, the only power is to cancel the licence. So can you invoke the regulatory provision without cancelling the licence," Justice Rajiv Sahai Endlaw asked the Centre while hearing over 150 petitions by pharma companies challenging government's March 10 notification banning 344 FDCs, a decision which has been stayed by the judge in each case filed before him since March 14.
The ASG said that "irrespective of licence, if a drug or FDC has no therapeutic justification, then it has to be banned. There is no question of cancelling the licence. Administrative process of cancelling licence will go on and on and during that time the drug will continue to be sold in the market".
On the point of therapeutic justification, the ASG said often a patient may not require one of the ingredients in an FDC, yet he would have to take the medicine as it comes as a combination.
When this issue was put to the ASG, he said Centre would issue necessary instructions to state governments informing them of the stay order and added that the companies would also have to approach the states in their individual capacity.
He also added that the Centre cannot say what will happen in Tamil Nadu where the Madras High Court has refused to stay the notification.
You’ve hit your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app